SmartTRAK was on-site at NASS 2023 covering the latest spine trends including hosting the hottest reception in town, “Targeting the ASC, What Spine Companies Need to Know."

Shifting hospital-based procedures to the ambulatory surgery center (ASC) is one of the biggest opportunities for healthcare savings and the opportunity is especially great for spine given its high acuity procedures like lateral lumbar fusions, 360 fusions and total disc replacements (TDRs) according to the results of SmartTRAK’s recent survey of 30 ortho, spine and neurosurgeons. At this year’s North American Society (NASS) Annual Meeting held in Los Angeles, CA October 18-21, SmartTRAK hosted a standing-room-only reception for industry on the migration of spine procedures into the ASC titled “Targeting the ASC: What Manufacturers Need to Know,” which included panel discussions and presentations focused on the spine market and practice trends. In this article, SmartTRAK highlights the top takeaways from the reception and identifies the latest trends and innovations at NASS affecting growth in the US Spine Market. Topics covered in the article include:

• New Care Models Optimizing Outpatient Spine
• The Motion Preservation “Renaissance” was Hard to Miss
• MIS SI Joint Fusion Systems – A Plethora of Systems, New Devices Launching Ahead of 2024 Reimbursement Changes.
• Will New Interbody Technologies Displace the Need for Biologics?
• Deals Abound: Several Biologics Deals Announced at NASS and After

To download and read the complete "NASS 2023: Trends, Advancing Technologies and New Deals Shaping the Future of Spine" article by Kris Jacques,  SmartTRAK's GM, Spine, just click the button below.

Nevro* (NVRO) announced it acquired VYRSA Technologies*, a privately held company focused on the minimally invasive treatment of chronic sacroiliac joint (SI Joint) pain. According to the Company, VYRSA is the only SI joint company that manufactures and supports a complete portfolio of FDA-cleared, state-of-the-art SI joint fusion devices. The acquisition was signed and closed on Nov 30, 2023. 

NVRO paid $40MM at closing and agreed to pay up to an additional $35MM in cash or stock tied to milestones. NVRO CEO Kevin Thornal said VYRSA offers differentiated implants to the Company’s current call point of physicians and will help drive company growth, adding that the technology will help bring long-term pain relief to the 15-30% of people suffering with chronic low back pain associated with the SI joint.

The US MIS SI Joint Fusion Market is the fastest-growing segment in the US Spine Market and a growing number of pain physicians are performing these procedures. According to SmartTRAK’s recently published 2023 US MIS SI Joint Market Report, this market is projected to grow at +18% CAGR over the next five years and 53+ MIS SI Joint Fusion systems are now commercially available in the US. See 2023 MIS SI Joint Fusion Market Report*.

The Company also announced the closing of a six-year, $200MM term loan credit facility to be used to repurchase the majority of its 2025 Convertible Notes and for working capital and other corporate purposes. NVRO CFO Rod MacLeod noted that the Company was pleased to refinance a majority of its debt and push the maturity out to 2029 while limiting equity dilution to 2.6MM warrant shares. 

Ready to dive into one of the most rapidly expanding markets in the world of Spine? Welcome to the realm of SI Joint Fusion, a market poised for remarkable growth with a projected 5-year CAGR of +18%. At SmartTRAK, we’re excited to introduce you to this thriving sector and give you a sneak peek of our forthcoming in-depth market segment solution subscription.

Outlined below is a brief list highlighting some of the key insights awaiting you upon subscribing to SmartTRAK's innovative solution and the valuable knowledge it delivers:

• Market Overview (US only/MIS market only):
  - Incidence and Prevalence: Understand the scale of SI Joint Fusion cases.
  - Market Size: Explore the market's current size and potential.
  - Revenue/Procedure Forecast through 2027: Take a look at expected future growth by market segments; transfixing and non-transfixing.
  - Growth Trends: Stay ahead with insights into emerging trends.
• Competitive Landscape:
  - By System Type: Discover the differences between Transfixing and Non-transfixing.
  - 2022 ASP Data Summary: Gain access to crucial pricing information.
• National/Regional Site of Service Procedure Volume Data:
  - HOPD vs ASC vs. Inpatient: Know where these procedures are performed.     - Annual Trends from 2017: Track the historical data for insights. 
• Coding & Reimbursement - 2024 Outlook:
  - Anticipate changes in coding and reimbursement for the coming year.
• Why MIS SIJ Fusion Matters:
  Within the vast Spine landscape, the Minimally Invasive Surgery (MIS) SI Joint Fusion procedure category is the star of the show. Here's why:
  - Growing Awareness and Diagnosis: More individuals are recognizing SI joint pain as a significant issue.
  - Robust Clinical Data: The body of clinical evidence is expanding.
  - Increasing Reimbursement Coding: Hospitals, HOPDs, ASCs and Physician's offices.
• The Future of MIS SI Joint Fusion:
  Acceptance of the posterior/dorsal non-transfixing MIS SI fusion approach is on the rise. This process is set to drive procedural growth and popularity, particularly among interventional pain physicians at Ambulatory Surgical Centers (ASCs).
  
  

So are you ready to dive into one of the most rapidly expanding markets in the world of Spine? Don’t miss your chance to stay ahead of the curve in the booming world of SI Joint Fusion and Be The Expert! Just click the button below to find out more.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Spine Market Recap* are:

• Complete Q123 Spine Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Spine Companies' News, Revenues, Data, Charts and Market Shares
• Top Players' Performance
  •  JNJ/DePuy Synthes
  • Globus 
  • NuVasive 
  • Stryker
• Q123 Spine Trends
  • M&A Activity
  • New Products
  • Reimbursement Dynamics
• Regulatory Highlights
• Europe Regulatory Updates
• Clinical Study Progress

Orthofix and SeaSpine announced the completion of its merger in Q123 in which SeaSpine became a wholly owned subsidiary of Orthofix. In a recent note, Canaccord Genuity highlighted SeaSpine, 7D Surgical and Simplify as the most notable of the recent spine acquisitions. SmartTRAK agrees and notes that ...

Read the entire Q123 Spine Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

In addition to product innovation and increasing adoption, the Spine Enabling Technology market is rapidly evolving due to mergers and acquisitions.

The Q123 WW Spine Enabling Tech Market was up +12.6% YoY, according to SmartTRAK Financial Dashboard. Medtronic (MDT) remained the market leader with 54.9% share, followed by Globus Medical (GMED) and other enabling tech competitors like Brainlab and Stryker (SYK). For detailed Q123 revenues and shares by company in the US, EU and ROW, see SmartTRAK Spine Enabling Tech Financial Dashboard*.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 US Spine Enabling Technology Market Recap* are:

• Complete Q123 Spine Enabling Tech Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Companies' News, Revenues, Data, Charts and Market Shares
• Mergers and Acquisitions Changing the Spine Enabling Technology Landscape
• New Spine Robots on the Horizon
• Milestones in Augmented Reality
• Q123 Regulatory Highlights

In February 2023, GMED announced it entered into a definitive agreement to combine in an all-stock transaction with NuVasive (NUVA). The transaction is expected to close mid-2023 subject to shareholder and regulatory agency approvals, which will make the combined company the ...

Read the entire Q123 Spine Enabling Tech Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

The ISASS 2023 annual meeting is taking place this week in San Francisco, and SmartTRAK is excited to be in attendance. Our team of spine experts will be roaming the event, providing our subscribers with up-to-the-minute news directly from the show floor. To ensure you're well-informed ahead of the meeting, below is a selection of recent spine news meticulously curated by our expert analysts at SmartTRAK.

If you're interested in receiving 30 days of COMPLIMENTARY daily real-time updates delivered to your inbox each morning, simply click here. Additionally, if if you are interested in learning more about The Future of Spine Enabling Technology for 2023, click here to read the article.

New Products:

• Orthofix*
  

  Orthofix noted that the Company launched the Lattus Lateral Access System and the Fathom Pedicle-Based Retractor System during Q123, which both address what the Company estimated to be a $1.8B MIS spine market.
  

• REFLECT Scoliosis System* - Globus*

  Globus Medical has announced FDA approval of REFLECT Scoliosis Correction System, the company's first humanitarian device. The non-fusion system, using a flexible cord instead of rigid metal rods, corrects scoliosis in young pts while preserving motion and allowing for growth.
  

Merger mayhem of Q422 continues and the Spine enabling tech space heats up with new navigation products and some robotics players seeing record-breaking sales and unit placements.

The Q422 WW Spine Enabling Tech Market was up +13.6% YoY, according to SmartTRAK Financial Dashboard. Medtronic (MDT) remained the market leader, followed by Globus Medical (GMED) and other enabling tech competitors like Brainlab and Stryker (SYK). For detailed Q422 revenues and shares by company in the US, EU and ROW, see SmartTRAK Spine Enabling Tech Financial Dashboard*.

• Complete Q422 Spine Enabling Tech Performance Recap
• Mighty Mergers in Q422 and Q123
  • SeaSpine and Orthofix Take the Plunge
  • Globus and NuVasive Join Forces in Q123
    
• Other Q422 Collaborations
  • ZimVie and Brainlab
  • Spineart and eCential Robotics
  • Captiva Spine and REMEX Medical
• Q422 Augmented Reality and Navigation Regulatory Highlights

Read the entire Q422 Spine Enabling Tech Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

More than just robots. Targeting enabling technologies to the ASC setting, development of novel assistive technologies, next-generation software updates, new applications and data insights abound at AAOS 2023.

In the US Markets for Spine and Orthopedic Enabling Technologies, it’s clear that companies are rapidly innovating and designing next-generation technologies that continue to advance the market well beyond the robotic surgical arms and platforms developed in the last decade. At this year’s American Academy of Orthopaedic Surgeons’ (AAOS) Annual Meeting, enabling technology was a big focus both on the podium and the exhibit floor. The Canaccord Genuity (CG) Musculoskeletal Conference also included a number of presentations from companies with innovative enabling technologies, including Enovis, OnPoint Surgical, THINK Surgical, OrthAlign, Augmedics, Canary Medical and newcomer Caira. Additionally, several companies on the AAOS exhibit floor were showcasing new developments across surgical planning, navigation, augmented reality, robotics and smart implants. In this Perspective article, SmartTRAK focuses in on several of the aforementioned companies, exciting technologies and important topics, including:

• These Are Not Your Father’s Robots: They're Here to Stay
• ASC Shift Driving Smaller, More Cost-Effective Solutions
• Dream Becoming Reality: Augmented Reality Competition Heats Up
• More Than Just Data: Smart Implants Show Promise in Improving Post-op Recovery
• Enabling Technology Space Continues to Grow
• Physician Adoption

With a lot of new developments expected later this year and over the next 24-48 months, the enabling technology space continues to grow and physician adoption is ...

To download and read the complete and unedited "Beyond Robotics: Enabling Tech Innovations at AAOS 2023" article by Elise Wolf, GM & VP, SmartTRAK Orthopedics, Digital & Quality, just click the button below.